Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRX 518

Drug Profile

TRX 518

Alternative Names: Anti-GITR monoclonal antibody - Leap Therapeutics; Anti-GITR-mAB; Anti-human-GITR-monoclonal-antibody; Anti-TNFRSF18 monoclonal antibody; TRX518

Latest Information Update: 13 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tolerx
  • Developer GITR Inc; Leap Therapeutics; Merck KGaA; Pfizer
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action T lymphocyte stimulants; TNFRSF18 protein stimulants; Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Ovarian cancer; Prostate cancer
  • Phase I Solid tumours
  • No development reported Malignant melanoma; Viral infections

Most Recent Events

  • 01 Jul 2019 Leap Therapeutics initiates enrolment in a phase I/II clinical trial in Solid tumours including Prostate cancer, Ovarian cancer, and Breast cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03861403)
  • 15 May 2019 Phase I/II clinical trials in Breast cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03861403)
  • 15 May 2019 Phase I/II clinical trials in Ovarian cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03861403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top